ABOS - Acumen Pharmaceuticals, Inc.

2.26
-0.290   -12.832%

Share volume: 919,327
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$2.55
-0.29
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-16.61%
1 Month
-31.52%
3 Months
13.00%
6 Months
43.04%
1 Year
89.92%
2 Year
-44.20%
Key data
Stock price
$2.26
P/E Ratio 
N/A
DAY RANGE
$2.25 - $2.55
EPS 
-$1.94
52 WEEK RANGE
$0.86 - $3.60
52 WEEK CHANGE
$105.45
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
72.213 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$614,764
AVERAGE 30 VOLUME 
$882,073
Company detail
CEO: Daniel J. O'Connell
Region: US
Website: acumenpharm.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage.

Recent news